Clinical Trials

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer. CTMS# 18-0085

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Kate Lathrop M.D.

For more information about this study
View Details

About This Study